Additive prognostic value of carbohydrate antigen-125 over frailty in patients undergoing transcatheter aortic valve replacement.
Francisco José RomeoIgnacio Miguel SeropianJuan Guido ChiabrandoJuan Valle RaleighMaximiliano SmietnianskyMariela CalMariano FalconiVadim KotowiczCarla Romina AgatielloDaniel Horacio BerrocalPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
CA-125, a tumor biomarker, outperformed frailty for predicting the primary endpoint within the first year after TAVR.